Tippapatt Alvotech ( NASDAQ: ALVO ) and Stada are extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia/Xgeva (denosumab) medicines for osteoporosis and cancer-related bone loss respectively, the companies said on Tuesday. Alvotech ( ALVO ) will be responsible for development and manufacturing at its facility in Reykjavik, Iceland. Stada will become marketing authorization holder, upon approval of AVT03, and will assume semi-exclusive commercial rights in Europe, including Switzerland and the UK, as well as exclusive commercial rights in selected countries in Central Asia and the Middle East.
In parallel with the commercial agreement for AVT03, the two partners have agreed to extend Stada’s commercial rights to biosimilars to AbbVie's ( ABBV ) top-selling arthritis drug Humira (adalimumab) and Johnson & Johnson’s ( JNJ ) Stelara (ustekinumab) to Commonwealth of Independent States countries in Central Asia. Alvotech ( ALVO ) will also regain commercial rights from STADA to AVT06, a proposed biosimilar to Eylea (aflibercept). Source: Press Release More on Alvotech Alvotech (ALVO) Q1 2024 Earnings Call Transcript Alvotech 2024 Q1 - Results - Earnings Call Presentation Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech enters $965M refinancing agreement Alvotech and Dr.
Reddy’s collaborate for commercialization of denosumab.